Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Impaired Immune Function in Myeloma
Impaired Immune Function in Myeloma
What do myeloma patients do when chemotherapy impairs their immune function? Not only does an impaired immune system cause fatigue but it also increases the risk of infection, a serious side effect causing more than a quarter of early MM deaths.
According to the studies linked below HemoHim can enhance immune function, reduce fatigue and is safe to use as a functional food.
HemoHIM – Immune System / Atomy HemoHIM / HemoHIM Review
I am a long-term MM survivor. Email me at David.PeopleBeatingCancer@gmail.com to learn more about both conventional and non-conventional therapies.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Effect of herbal preparation HemoHIM on fatigue level and exercise performance: A randomized, placebo-controlled, double-blind, and parallel clinical trial
Introduction
The herbal preparation HemoHIM, which is a mixture of traditional Korean medicinal plants, has been proven effective in enhancing exercise performance and reducing fatigue levels in mice. Therefore, this study aimed to evaluate the effect of HemoHIM on fatigue levels and exercise performance in healthy human adults.
Methods
Ninety-six adults with fatigue were recruited for this study. In visit 1, maximal oxygen consumption was measured using a cycle ergometer test to assess eligibility. Participants were randomly assigned to the HemoHIM group (HG, n = 48) or the placebo group (PG, n = 48) in visit 2. Each participant consumed HemoHIM or a placebo twice per day for 8 weeks and visited the laboratory four times. Body composition, vital signs, dietary intake, fatigue level (fatigue severity scale, [FSS]), cardiorespiratoryendurance, muscle strength, blood biomarkers, and adverse events were measured at each visit.
Results
HemoHIM significantly decreased the FSS scores compared to that of the PG at visit 3 (P=.019); this decrease was maintained until visit 4 (P=.002). The exercise distance to exhaustion in the HG significantly increased compared to that in the PG (P=.040). HemoHIM significantly increased lactate and creatinine levels immediately after the ergometer test (lactate P=.011, creatinine P=.019) and 30 min after the test (lactate P=.036, creatinine P=.002) compared to that in the PG.
Conclusion
This study demonstrated that HemoHIM reduced fatigue levels and improved exercise duration. The findings may have potential applications in the nutritional supplement industry in the future.
Evaluation of acute, 28-day, 13-week repeated dose oral toxicity and genotoxicity of a herbal extract (HemoHIM G) from Angelica sinensis, Ligusticum chuanxiong, and Peaonia lactiflora
Abstract
HemoHIM G is a functional food ingredient composed of a triple herbal combination of
- Angelica sinensis,
- Ligusticum chuanxiong,
- and Paeonia lactiflora,
to improve impaired immune function.
Considering the pharmacological benefits of its constituent herbal components, HemoHIM G is anticipated to have various health benefits; however, its toxicity has not been thoroughly evaluated. Here, we conducted a comprehensive study to assess the safety of HemoHIM G in terms of acute oral toxicity, 13-week repeat-dose toxicity, and genotoxicity.
In the oral acute toxicity study, Sprague-Dawley rats were orally administered a single dose of HemoHIM G at 5000 mg/kg/day, the limit dose for the acute study. No abnormal findings or adverse effects were observed in this study, as confirmed by gross pathology.
A 13-week repeated-dose toxicity study was conducted with HemoHIM G at doses of 1250, 2500, and 5000 mg/kg/day to examine the subchronic toxicity in both male and female rats after 28 days of dose-range finding study.
No test substance-related clinical signs or mortality was observed at any of the tested doses. Gross pathology, hematology, blood chemistry, and histopathology were within normal ranges, further supporting the safety of HemoHIM G…
HemoHIM G is non-mutagenic and non-clastogenic. Collectively, these findings provide valuable evidence for the safe use of HemoHIM G as a functional food ingredient.
impaired immune function in myeloma impaired immune function in myeloma impaired immune function in myeloma